Routine Blood Tests for Patients Taking SGLT2 Inhibitors Show Modest Red Blood Cell Increases
Patients taking sodium-glucose cotransporter 2 (SGLT2) inhibitors for type 2 diabetes, heart failure, or chronic kidney disease may notice slight elevations in their red blood cell metrics on routine lab work, according to a systematic review published October 24 in JAMA. The meta-analysis pooled 85 randomized clinical trials involving 70,543 adults, revealing that these medications trigger modest rises in both hemoglobin and hematocrit.
Medical Daily noted that the evaluated drugs comprise empagliflozin (Jardiance), dapagliflozin (Farxiga), canagliflozin (Invokana), ertugliflozin (Steglatro), sotagliflozin (Inpefa), and bexagliflozin (Brenzavvy). Participants across the studies averaged roughly 62 years of age, with women making up about 36% of the total cohort. Trials spanned North America, Europe, and Asia, with 38 studies incorporating at least one U.S. clinical site.
Contrasting Findings Between Treatment and Control Groups Across 85 Trials
The primary outcomes of the meta-analysis demonstrated statistically significant differences in red blood cell markers between patients receiving SGLT2 inhibitors and those in control groups over a median follow-up of 24 weeks. Hemoglobin increased by 0.55 g/dL from baseline in the treatment group, compared with a drop of 0.08 g/dL in controls, yielding a between-group difference of 0.60 g/dL. Medical Daily similarly highlighted that these medications raised hemoglobin by about 0.6 grams per deciliter.
Hematocrit rose by 2.17% among patients taking SGLT2 inhibitors, whereas control arms experienced a 0.13% decline, establishing a between-group difference of 2.36%. Secondary outcomes tracked by the researchers further illuminated the physiological shift. Erythropoietin (EPO) climbed by 2.35 mIU/mL in treated participants compared with 0.04 mIU/mL in controls. Meanwhile, transferrin saturation dropped by 2.2% in the treatment group against a 0.10% shift in control subjects.
Iron Metabolism Shifts Trigger Unclear Clinical Implications
The observed changes point toward the body drawing on iron stores to manufacture new red blood cells, as evidenced by the drop in transferrin saturation paired with rising EPO levels. However, the exact clinical significance of these alterations remains unclear. While the statistical differences are large, the analysis did not establish whether the lab increases translate directly to measurable clinical benefits or risks for patients.
Medical Daily reported that the adjustments are often temporary and generally do not correlate with worse outcomes, though small sample sizes for specific secondary endpoints limit firm conclusions. An accompanying editorial in JAMA suggested that the modest rise could contribute to anemia management, yet researchers caution that further study is required to determine if the effect predominantly helps or occasionally harms patients.
Patients Must Consult Clinicians Before Altering SGLT2 Therapy
Medical Daily emphasized that patients should not stop or alter their SGLT2 inhibitor regimen independently based on routine blood test results. These therapies reduce the risk of heart failure hospitalizations and kidney decline for many people, meaning abrupt discontinuation could eliminate vital organ protection. Anyone seeing unexpected shifts in their hemoglobin test results should consult the prescribing clinician.
Researchers emphasize that current treatment guidelines remain unchanged by the new data. Clinicians must weigh the cardiorenal benefits of the medications against potential lab-value adjustments like erythrocytosis. Further investigation is needed to clarify the implications of these haematological changes for patients receiving SGLT2 inhibitor therapy.
Common Questions Regarding Blood Metrics and SGLT2 Inhibitor Therapy
What specific lab changes do SGLT2 inhibitors cause?
The JAMA review of 85 trials found that SGLT2 inhibitors increased hemoglobin by about 0.6 g/dL and hematocrit by roughly 2.4 percentage points compared with control treatments over a median of 24 weeks.
Which medications fall under the SGLT2 inhibitor class?
Evaluated drugs include empagliflozin (Jardiance), dapagliflozin (Farxiga), canagliflozin (Invokana), ertugliflozin (Steglatro), sotagliflozin (Inpefa), and bexagliflozin (Brenzavvy), which are prescribed for type 2 diabetes, heart failure, or chronic kidney disease.
Are elevated hemoglobin levels dangerous for patients taking these drugs?
The changes are typically small and often temporary, but in some individuals they can lead to erythrocytosis, which may elevate clotting risks. Doctors evaluate these individual trade-offs during routine checkups.
Related reading